TRAW:NASDAQ, Traws Pharma, Inc.

Why TRAW stock rose on November 12

Traws Pharma, Inc. rose 12.0% on Thursday, November 12, 2026, on 682,400 shares. Headlines around the move:

TRAW stock overview

Traws Pharma, Inc. (TRAW:NASDAQ) closed at $0.260 on November 16, 2026, up 3.59% on the day. The stock trades 92.0% below its 52-week high of $3.23 and 18.2% above its 52-week low of $0.220. Over the past year, it lost 87.8%. Traws Pharma, Inc. is part of the Health Care sector.

Key figures

Price
$0.260
Day change
+3.59%
Volume
209,873
Average volume
604,518
Market cap
3M+
52-week range
$0.220 – $3.23
50-day average
$0.428
200-day average
$1.06

Price action over the past year

In 252 trading sessions since November 14, 2025, TRAW closed higher on 105 days (42%). Its best day was May 8, 2026 (+28.24%) and its worst was June 15, 2026 (-40.63%). The stock moved 10% or more in a single session 36 times. It opened at least 5% above the previous day's high 3 times.

Recent signals

TRAW news

About Traws Pharma, Inc.

Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.

Similar stocks

Find more stocks like TRAW with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.